Table 3.

UL97 Genotyping in Nonresponders Who Received >14 Days of Maribavir

	Both Trials	Trial 202				Trial 203
Characteristic	All Doses	All Doses	400 mg	800 mg	1200 mg	All Doses	400 mg	800 mg	1200 mg
Nonresponders who received maribavir for >14 d	39	26	11	11	4	13	5	5	3
Patients with UL97 follow-up genotyping data	25	16	7	6	3	9	3	4	2
Median treatment duration, d	55	62	61	59	70	46	45	58	49
Median starting CMV load, copies/mL	40 000	50 000	50 000	30 000	200 000	14 500	14 500	155 000	11 500
Median study day at follow-up genotyping	58	59	59	59	58	54	46	68	50
Study day range at follow-up	15–140	15–140	15–140	47–116	52–91	21–83	46–53	54–83	21–78
UL97 mutation detected, Noa
T409M	7 (28%)	5	1	3b	1	2	0	2	0
H411Y	2 (8.3%)	2	1	1	0	0	0	0	0
C480F	5 (21%)	3	0	3b	0	2	1	0	1
T409M, H411Y or C480F	13 (52%)	9	2	6	1	4	1	2	1
F342Y	1			1c

Abbreviation: CMV, cytomegalovirus.

^aPercentages based on number with available UL97 genotyping data.

^bOne patient had both UL97 C480F and T409M detected.

^cThis mutation was present at baseline and later detected in combination with H411YJ.